BioSpace News Archive

Daxor Corporation, the global leader in blood volume measurement technology, announces new data from Banner University Medicine Advanced Heart Failure Clinic in Phoenix, AZ validating the benefits of the Company’s BVA-100 diagnostic blood test for ambulatory patients with advanced heart failure.

Harmony Biosciences Holdings, Inc., a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, announced that it has completed its acquisition of Zynerba Pharmaceuticals, Inc.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will present study findings during two posters sessions at IDWeek 2023, October 11-15.

Femasys Inc. announced that it has it has received notice from The Nasdaq Stock Market LLC informing Femasys that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550 for continued listing on The Nasdaq Capital Market.

ZyVersa Therapeutics, Inc. announces publication of a paper in the peer-reviewed journal, Nature Reviews Nephrology, that summarizes data highlighting how lipid accumulation in the kidneys contributes to CKD development and disease progression.

Kazia Therapeutics Limited, an oncology-focused drug development company, announces its intention to de-list from the Australian Securities Exchange.

Cellares, the first Integrated Development and Manufacturing Organization dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy leader Bristol Myers Squibb will enter a second proof-of-concept tech transfer process for the manufacture of a CAR-T cell therapy, as part of the Cellares Technology Adoption Partnership program.

Glaukos Corporation plans to release third quarter 2023 financial results after the market close on Wednesday, November 1, 2023.

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, announced the details of two poster presentations at IDWeek 2023, being held virtually and in person in Boston, MA on October 11-15.

PDS Biotechnology Corporation announced interim safety and immune response data for the first-in-human Phase 1/2 clinical trial evaluating PDS0301, a novel investigational tumor-targeting, antibody-conjugated Interleukin 12, in combination with current standard-of-care chemotherapy, docetaxel, to treat metastatic castration sensitive and castration resistant prostate cancer.